* Kronos Bio Inc reported a quarterly adjusted loss of 23 cents per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of -54 cents. The mean expectation of four analysts for the quarter was for a loss of 28 cents per share. Wall Street expected results to range from -32 cents to -20 cents per share.
* Revenue rose 158.5% to $2.37 million from a year ago; analysts expected $2.10 million.
* Kronos Bio Inc's reported EPS for the quarter was a loss of 23 cents.
* The company reported a quarterly loss of $14.11 million.
* Kronos Bio Inc shares had fallen by 8.0% this quarter and lost 26.4% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had fallen by about 1.5% in the last three months.
* In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."
* The average consensus recommendation for the biotechnology & medical research peer group is also "buy"
Wall Street's median 12-month price target for Kronos Bio Inc is 1.63 This summary was machine generated from LSEG data November 14 at 04:01 a.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Sep. 30 2024 -0.28 -0.23 Beat
Jun. 30 2024 -0.34 -0.27 Beat
Mar. 31 2024 -0.42 -0.29 Beat
Dec. 31 2023 -0.52 -0.34 Beat
Comments